Survival effect of first- and second-line treatments for patients with primary glioblastoma: A cohort study from a prospective registry, 1997-2010

Neuro-Oncology

Volumn 16, Issue 5, 2014, Pages 719-727

  Nava, Francesca ^a   Tramacere, Irene ^a   Fittipaldo, Andrea ^a   Bruzzone, Maria Grazia ^a   Dimeco, Francesco ^a,b   Fariselli, Laura ^a   Finocchiaro, Gaetano ^a   Pollo, Bianca ^a   Salmaggi, Andrea ^c   Silvani, Antonio ^a   Farinotti, Mariangela ^a   Filippini, Graziella ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c A MANZONI HOSPITAL   (Italy)

Author keywords

Glioblastoma; Surgery; Survival analysis; Treatment effectiveness; Treatments

Indexed keywords

BEVACIZUMAB; FOTEMUSTINE; MITOXANTRONE; PROCARBAZINE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BRAIN BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COMPARATIVE STUDY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HAZARD RATIO; HUMAN; HUMAN TISSUE; ITALY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIMARY GLIOBLASTOMA; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIOSURGERY; REOPERATION; SURVIVAL RATE; THERAPY EFFECT; ADJUVANT CHEMOTHERAPY; BRAIN NEOPLASMS; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; PROGNOSIS; REGISTER; SURVIVAL; TUMOR RECURRENCE;

AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES; SURVIVAL ANALYSIS;

EID: 84899450186     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not316     Document Type: Article

References (47)

1. Louis DN Ohgaki H Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109
2. Jemal A Siegel R Xu J Ward E. Cancer statistics 2010. CA Cancer J Clin. 2010;60(5):277-300
3. Filippini G. Epidemiology of primary central nervous system tumors. Handb Clin Neurol. 2012;104:3-22
4. Ohgaki H Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109(1):93-108
5. Helseth R Helseth E Johannesen TB et al. Overall survival prognostic factors and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. Acta Neurol Scand. 2010;122(3):159-167
6. Gorlia T van Den Bent MJ Hegi ME et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008;9(1):29-38
7. Stupp R Mason WP van Den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996
8. Stark AM van De Bergh J Hedderich J et al. Glioblastoma: Clinical characteristics prognostic factors and survival in 492 patients. Clin Neurol Neurosurg. 2012;114(7):840-845
9. Gerstein J Franz K Steinbach JP et al. Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-Term outcome of unselected patients from a single institution. Strahlenther Onkol. 2011;187(11):722-728
10. Lamborn KR Yung WK Chang SM et al. Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008;10(2):162-170
11. Friedman HS Prados MD Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740
12. Vredenburgh JJ Desjardins A Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722-4729
13. U.S.: BL 125085/169 amendment: Bevacizumab-Genentech inc. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 125085s0169lbl.pdf. Accessed October 3 2013
14. Patel M Siddiqui F Jin JY et al. Salvage reirradiation for recurrent glioblastoma with radiosurgery: Radiographic response and improved survival. J Neurooncol. 2009;92(2):185-191
15. Fogh SE Andrews DW Glass J et al. Hypofractionated stereotactic radiation therapy: An effective therapy for recurrent high-grade gliomas. J Clin Oncol. 2010;28(18):3048-3053
16. Clarke JL Ennis MM Yung WK et al. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?. Neuro Oncol. 2011;13(10):1118-1124
17. Filippini G Falcone C Boiardi A et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol. 2008;10(1):79-87
18. Stark AM Nabavi A Mehdorn HM et al. Glioblastoma multiforme-report of 267 cases treated at a single institution. Surg Neurol. 2005;63(2):162-169; discussion 169
19. Park CK Kim JH Nam DH et al. A practical scoring system to determine whether to proceed with surgical resection in recurrent glioblastoma. Neuro Oncol. 2013;15(8):1096-1101
20. Lonjon N Bauchet L Duffau H et al. [Second surgery for glioblastoma. A 4-year retrospective study conducted in both the Montpellier and Nice Departments of Neurosurgery. A literature review]. [Article in French] Neurochirurgie. 2010;56(1):36-42
21. Okita Y Narita Y Miyakita Y et al. Pathological findings and prognostic factors in recurrent glioblastomas. Brain Tumor Pathol. 2012;29(4):192-200
22. Hegi ME Diserens AC Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10): 997-1003
23. Olson RA Brastianos PK Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: A systematic review and meta-Analysis. J Neurooncol. 2011;105(2): 325-335
24. Macdonald DR Cascino TL Schold SC Jr et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280
25. Wen PY Macdonald DR Reardon DA et al. Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11): 1963-1972
26. Eoli M Menghi F Bruzzone MG et al. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res. 2007;13(9):2606-2613
27. Cox DR. Regression models and life tables (with discussion). J Roy Statist Soc Ser B. 1972;34:187-220
28. Clark TG Altman DG De Stavola BL. Quantification of the completeness of follow-up. Lancet. 2002;359(9314):1309-1310
29. Ward LC Fielding JW Dunn JA et al. The selection of cases for randomised trials: A registry survey of concurrent trial and non-Trial patients. The British Stomach Cancer Group. Br J Cancer. 1992;66(5):943-950
30. Goyal J Nuhn P Huang P et al. The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer. BJU Int. 2012;110(11 Pt B): E575-E582
31. Ronning PA Helseth E Meling TR et al. A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. Neuro Oncol. 2012;14(9):1178-1184
32. van Genugten JA Leffers P Baumert BG et al. Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice. J Neurooncol. 2010;96(2):249-257
33. Johnson DR ONeill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol. 2012; 107(2):359-364
34. Fabrini MG Silvano G Lolli I et al. A multi-institutional phase II study on second-line fotemustine chemotherapy in recurrent glioblastoma. J Neurooncol. 2009;92(1):79-86
35. Addeo R Caraglia M De Santi MS et al. A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. J Neurooncol. 2011;102(3):417-424
36. Reithmeier T Graf E Piroth T et al. BCNU for recurrent glioblastoma multiforme: Efficacy toxicity and prognostic factors. BMC Cancer. 2010;10:30
37. Brandes AA Ermani M Basso U et al. Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: A phase II study. Oncology. 2002; 63(1):38-41
38. Mineo JF Bordron A Baroncini M et al. Prognosis factors of survival time in patients with glioblastoma multiforme: A multivariate analysis of 340 patients. Acta Neurochir (Wien). 2007;149(3): 245-252 discussion 252-253
39. Durmaz R Erken S Arslantas A et al. Management of glioblastoma multiforme: With special reference to recurrence. Clin Neurol Neurosurg. 1997;99(2):117-123
40. Grobbee DE Hoes AW. Confounding and indication for treatment in evaluation of drug treatment for hypertension. BMJ. 1997; 315(7116):1151-1154
41. Carson KA Grossman SA Fisher JD et al. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol. 2007; 25(18):2601-2606
42. Barbagallo GM Jenkinson MD Brodbelt AR. Recurrent glioblastoma multiforme when should we reoperate?. Br J Neurosurg. 2008;22(3): 452-455
43. Park JK Hodges T Arko L et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol. 2010;28(24): 3838-3843
44. Weller M Stupp R Hegi ME et al. Personalized care in neuro-oncology coming of age: Why we need MGMTand 1p/19q testing for malignant glioma patients in clinical practice. Neuro Oncol. 2012;14:(Suppl 4): Iv100-iv108
45. Deeks JJ Dinnes J DAmico R et al. Evaluating non-randomised intervention studies. Health Technol Assess. 2003;7(27):iii-x 1-173
46. Moons KG Royston P Vergouwe Y et al. Prognosis and prognostic research: What why and how?. BMJ. 2009;338:b375
47. Hannan EL. Randomized clinical trials and observational studies: Guidelines for assessing respective strengths and limitations. JACC Cardiovasc Interv. 2008;1(3):211-217.